{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:12Z","timestamp":1792740612900,"version":"4.5.0"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>DTaP5-IPV-Hib-HepB is a fully liquid investigational hexavalent vaccine directed against 6 diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>This multicenter, open-label, comparator-controlled, phase III study randomly assigned healthy infants 2-to-1 as follows: group 1 received DTaP5-IPV-Hib-HepB, PCV13, and RV5 at 2, 4, and 6 months of age followed by DTaP5, Hib-OMP, and PCV13 at 15 months of age; group 2 received DTaP5-IPV\/Hib, PCV13, and RV5 at 2, 4, and 6 months of age, with HepB at 2 and 6 months of age, followed by DTaP5, Hib-TT, and PCV13 at 15 months of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Overall, 981 participants were vaccinated in group 1 and 484 in group 2. Immune responses in group 1 to all antigens contained in DTaP5-IPV-Hib-HepB 1 month after dose 3 and for concomitant rotavirus vaccine were noninferior to those in group 2, with the exception of antipertussis filamentous hemagglutinin (FHA) geometric mean concentrations (GMCs). Vaccine response rates for FHA were noninferior to control. After the toddler dose, group 1 immune responses were noninferior to group 2 for all pertussis antigens. Solicited adverse event rates after any dose were similar in both groups, with the exceptions of increased injection-site erythema, increased fever, and decreased appetite in group 1. Fever was not associated with hospitalization or seizures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>The safety and immunogenicity of DTaP5-IPV-Hib-HepB are comparable with the analogous licensed component vaccines. Decreased FHA GMCs and increased injection-site reactions and fever are unlikely to be clinically significant. DTaP5-IPV-Hib-HepB provides a new combination vaccine option aligned with the recommended US infant immunization schedule.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2014-4102","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:19:27Z","timestamp":1438042767000},"page":"e323-e332","source":"Crossref","is-referenced-by-count":33,"title":["Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants"],"prefix":"10.1542","volume":"136","author":[{"given":"Gary S.","family":"Marshall","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Louisville, Louisville, Kentucky;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Adams","sequence":"additional","affiliation":[{"name":"Blue Ridge Pediatric and Adolescent Medicine, Boone, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Leonardi","sequence":"additional","affiliation":[{"name":"Palmetto Pediatrics, Charleston, South Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petrecz","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl A.","family":"Flores","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"Ngai","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghan","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginamarie","family":"Foglia","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Swiftwater, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Lee","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"issue":"5","key":"2021120906092672100_B1","first-page":"108","article-title":"Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years\u2014United States, 2014.","volume":"63","author":"Akinsanya-Beysolow","year":"2014","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"key":"2021120906092672100_B2","unstructured":"Centers for Disease Control and Prevention. Immunization schedules. Available at: www.cdc.gov\/vaccines\/schedules\/hcp\/child-adolescent.html. Accessed December 10, 2014"},{"key":"2021120906092672100_B3","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1542\/peds.2010-1722N","article-title":"Vaccine attitudes, concerns, and information sources reported by parents of young children: results from the 2009 HealthStyles survey.","volume":"127","author":"Kennedy","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"2021120906092672100_B4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0749-3797(03)00093-X","article-title":"Predictors of age-appropriate receipt of DTaP dose 4.","volume":"25","author":"Strine","year":"2003","journal-title":"Am J Prev Med"},{"issue":"2","key":"2021120906092672100_B5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ypmed.2004.12.001","article-title":"Do too many shots due lead to missed vaccination opportunities? Does it matter?","volume":"41","author":"Meyerhoff","year":"2005","journal-title":"Prev Med"},{"issue":"2","key":"2021120906092672100_B6","first-page":"1","article-title":"General recommendations on immunization\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"60","author":"Kroger","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"2021120906092672100_B7","unstructured":"American Academy of Pediatrics. Combination vaccines. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book Online: Report of the Committee on Infectious Diseases. Available at: http:\/\/redbook.solutions.aap.org\/chapter.aspx?sectionid=56798095&bookid=886. Accessed October 31, 2014"},{"key":"2021120906092672100_B8","unstructured":"American Academy of Family Physicians Web site. Immunization schedules. Available at: www.aafp.org\/patient-care\/immunizations\/schedules.html. Accessed October 31, 2014"},{"issue":"6","key":"2021120906092672100_B9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates.","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2021120906092672100_B10","first-page":"506","article-title":"Combination vaccine use and vaccination quality in a managed care population.","volume":"13","author":"Happe","year":"2007","journal-title":"Am J Manag Care"},{"issue":"2","key":"2021120906092672100_B11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/INF.0b013e318187d047","article-title":"Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.","volume":"28","author":"Happe","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120906092672100_B12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.","volume":"149","author":"Anderson","year":"1984","journal-title":"J Infect Dis"},{"issue":"6","key":"2021120906092672100_B13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"issue":"20","key":"2021120906092672100_B14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","article-title":"Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.","volume":"16","author":"Storsaeter","year":"1998","journal-title":"Vaccine"},{"issue":"2","key":"2021120906092672100_B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates.","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"1","key":"2021120906092672100_B16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/INF.0b013e3182717edf","article-title":"Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.","volume":"32","author":"Tapi\u00e9ro","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2021120906092672100_B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity.","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"27\u201328","key":"2021120906092672100_B18","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1016\/j.vaccine.2008.04.016","article-title":"Prediction of pertussis vaccine efficacy using a correlates of protection model.","volume":"26","author":"Kohberger","year":"2008","journal-title":"Vaccine"},{"key":"2021120906092672100_B19"},{"issue":"9","key":"2021120906092672100_B20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/01.inf.0000232635.81312.06","article-title":"The impact of DTaP-IPV-HB vaccine on use of health services for young infants.","volume":"25","author":"Thompson","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120906092672100_B21","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-1977","article-title":"A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.","volume":"122","author":"Zangwill","year":"2008","journal-title":"Pediatrics"},{"key":"2021120906092672100_B22","unstructured":"Immunization Action Coalition. Ask the experts: diseases & vaccines. Diphtheria, tetanus, pertussis. Available at: www.immunize.org\/askexperts\/experts_per.asp. Accessed December 3, 2014"},{"issue":"6","key":"2021120906092672100_B23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/erv.09.32","article-title":"Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV\/Hib hexavalent vaccine).","volume":"8","author":"Zepp","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"2021120906092672100_B24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.inf.0000222413.47344.23","article-title":"The use of combination vaccines has improved timeliness of vaccination in children.","volume":"25","author":"Kalies","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"20","key":"2021120906092672100_B25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.vaccine.2008.03.001","article-title":"Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany\u2019s experience after 5 years of licensure.","volume":"26","author":"Kalies","year":"2008","journal-title":"Vaccine"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/136\/2\/e323\/918130\/peds_2014-4102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/136\/2\/e323\/918130\/peds_2014-4102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:23:32Z","timestamp":1639095812000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/136\/2\/e323\/33751\/Immunogenicity-Safety-and-Tolerability-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,8,1]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-4102","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}